Welcome to Changzhou Ruiming Pharmaceutical Co.,Ltd

Content

1. Brief Introduction
2. Milestone
3. Management system
4. Personnel
5. Product

1.Brief Introduction

Changzhou Ruiming Pharmaceutical is located at No.1558, Longjiang Bei Road, Changzhou City , Xinbei District China-213127 Chunjiang Town, Jiangsu Province

FEI: 3007086821

DUNS: 528186718

The company is beside of Yangtze river and high way of Shanghai to Nanjing, with a convenient transportation.

There is no high toxic or highly sensitized product at the around plant.

Location


S232
团结镇
建山镇
S336
虹桥镇
S336
广靖高速
靖江市
A
新桥镇
S338
S39
沪宁高速
春江镇
S338
江阴市
奔牛机场
临港街道
G312
S340
京沪高速
S239
常州机场申
通薛家分部
涂镇
新北区
常州市
常合高速
S229
钟楼区
G2
天宁区
G42
S340
青阳镇
戚墅堰区
G312
S38

The company was built in 2005 with the investment of RMB 50 millions.

The APIs with high technology, high value added and low pollution are the major target of the company. The design and building of the whole plant meets the GMP requirement.

The total area of company is 25,000m^2, and the green area is more than40%.

The plant is partitioned into production area (Synthesis area and clean area), assistant facilities, warehouse and office. The human flow and material flow are separated. There are three buildings for API and intermediates synthesis and drying, and one building for API purification, drying and packaging (cleaning degree: D).

Layout of company



常州瑞明药业厂区平面布置图

2. Milestone

Time	Development
May 2005	Installed completed
Feb. 2008	Got Drug Manufacturing license and the scope is API. (苏20110162)
Nov. 2008	Got license number of Propafenone Hydrochloride (H20084524),
Jan. 2009	Got license number of Felodipine (H20093106)
Jul. 2009	Got GMP certificate of Propafenone Hydrochloride and Felodipine (K0774)
Apr. 2010	Tamsulosin Hydrochloride Got DMF number: 23741
Feb. 2011	Got license number of Amlodipine Besylate (H20113077)
July. 2011	Got GMP certificate of Amlodipine Besylate (JS20110008)
Aug. 2011	Got CEP for Amlodipine Besylate (R0-CEP 2008-074-Rev 00)
July .2015	Got renewal GMP certificate of Three API (JS20150443)
July.2016	Got EIR of Tamsulosin Hydrochloride from SFDA（FEI：3007086821）
Aug.2016	Got renewal CEP for Amlodipine Besilate （R1-CEP 2008-074-Rev 00）

Chinese renewal GMP Certificate of Three APIS

中华人民共和国

药品GMP证书

CERTIFICATE OF GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS
PEOPLE'S REPUBLIC OF CHINA

证书编号：JS20150443
Certificate No.

企业名称：常州瑞明药业有限公司
Manufacturer：Changzhou Ruiming Pharmaceutical Co., Ltd.

地　址：常州市新北区春江镇龙江北路1558号
Address：No. 1558, Longjiang Bei Road, Chunjiang Town, New-North District, Changzhou

认证范围：原料药[（盐酸普罗帕酮）、（非洛地平、苯磺酸氨氯地平）]
Scope of Inspection：Bulk Drug[(Propafenone Hydrochloride), (Felodipine, AmlodipineBesylate)]

经审查，符合中华人民共和国《药品生产质量管理规范》要求。
特发此证。
This is to certify that the above-mentioned manufacturer complies with the requirements of Chinese Good Manufacturing Practices for Pharmaceutical Products.

有效期至　2020 年 7 月 6 日
This certificate remains valid until 6 / 7 / 2020

发证机关：江苏省食品药品监督管理局
Issued By JIANGSU FOOD AND DRUG ADMINISTRATION

Date for Issuing 7 / 7 / 2015　　2015 年 7 月 7 日

国家食品药品监督管理总局制
CHINA FOOD AND DRUG ADMINISTRATION

EIR of SFDA

DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Compliance
Office of Manufacturing Quality
Division of Drug Quality II
10903 New Hampshire Avenue
Building #51, Room 4359
Silver Spring, MD 20993

TELEPHONE: (240) 402-4593
FAX: (301) 847-8742

July 21, 2016

Reference: Inspection Dates July 13, 2015 – July 17, 2015
Location: Changzhou Ruiming Pharmaceuticals Co. Ltd.
No. 1558 Longjiang North Road
Chunjiang Town, Xinbei District
Changzhou, Jiangsu, 213127 China

Dear Mr.Weiming:

We are enclosing a copy of the establishment inspection report (EIR) for the inspection that the U.S. Food and Drug Administration (FDA) conducted at your premises on the referenced locale and dates. When the Agency concludes that an inspection is "closed" under 21 CFR 20.64(d)(3), it will release a copy of the EIR to the inspected establishment. This procedure is applicable to EIRs for inspections completed on or after April 1, 1997.

The Agency continually works to make its regulatory process and activities more transparent to the regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 CFR Part 20. This, however, does not preclude you from requesting additional information under FOIA.

If you have any questions regarding this letter, you may contact me at the above address or number: 240-402-4593.

For more information on the U.S. FDA, please visit our website at www.fda.gov.

Sincerely,

Towanda Terrell

Towanda Terrell
Compliance Officer
Division of Drug Quality II

FEI: 3007086821
Enclosure: EIR

Renewal **CEP** of Amlodipine Besilate 1/3

Certification of Substances Division

Certificate of suitability
No. R1-CEP 2008-074-Rev 00

Name of the substance:
AMLODIPINE BESILATE

Name of holder:
CHANGZHOU RUIMING PHARMACEUTICAL CO., LTD.
No. 1558 Longjiang Bei Road
Changzhou City, Xinbei District
China-213 127 Chunjiang Town, Jiangsu Province

Site(s) of production:
SEE ANNEX 1

THIS CERTIFICATE SUPERSEDES THE PREVIOUS CERTIFICATE
R0-CEP 2008-074-REV 00

After examination of the information provided on the manufacturing method and subsequent processes (including purification) for this substance on the site(s) of production listed in annex, we certify that the quality of the substance is suitably controlled by the current version of the monograph **AMLODIPINE BESILATE** no. 1491 of the European Pharmacopoeia, current edition including supplements.

In the last steps of the synthesis ethanol is used as solvent. Its residual content is limited by the test for loss on drying (2.2.32) of the European Pharmacopoeia, with a limit of not more than 0.2%.

The re-test period of the substance is 2 years if stored in double polyethylene bags placed in paper drums.

The holder of the certificate has declared the absence of use of material of human or animal origin in the manufacture of the substance.

The submitted dossier must be updated after any significant change that may alter the quality, safety or efficacy of the substance.

Manufacture of the substance shall take place in accordance with the Good Manufacturing Practice and in accordance with the dossier submitted.

Failure to comply with these provisions will render this certificate void.

Address: 7 Allée Kastner, CS 30026
F-67081 Strasbourg (France)
Tel: +33 (0) 3 88 41 30 30 – Fax: +33 (0) 3 88 41 27 71 - e-mail: cep@edqm.eu
Internet: http://www.edqm.eu

Renewal **CEP** of Amlodipine Besilate 2/3



This certificate is renewed from **4 August 2016** according to the provisions of Resolution AP-CSP (07) 1, and of Directive 2001/83/EC and Directive 2001/82/EC and any subsequent amendment, and the related guidelines.

This certificate has one annex of 1 page.
This certificate has:
lines.

On behalf of the
Director of EDQM

Strasbourg, 2 August 2016

DECLARATION OF ACCESS *(to be filled in by the certificate holder under their own responsibility)*

CHANGZHOU RUIMING PHARMACEUTICAL CO., LTD., as holder of the certificate of suitability

R1-CEP 2008-074-Rev 00 for Amlodipine besilate

hereby authorises .....
(name of the pharmaceutical company),

to use the above-mentioned certificate of suitability in support of their application(s) for the following Marketing Authorisation(s): *(name of product(s) and marketing number(s), if known)*

The holder also certifies that no significant changes to the operations as described in the CEP dossier have been made since the granting of this version of the certificate.

Date and Signature *(of the CEP holder)*:

Address: 7 Allée Kastner, CS 30026
F-67081 Strasbourg (France)
Tel: +33 (0) 3 88 41 30 30 – Fax: +33 (0) 3 88 41 27 71 - e-mail: cep@edqm.eu
Internet: http://www.edqm.eu

Renewal **CEP** of Amlodipine Besilate 3/3



Certification of Substances Division

Annex 1: Site(s) of production for R1-CEP 2008-074-Rev 00

Production of Amlodipine besilate:
CHANGZHOU RUIMING PHARMACEUTICAL CO., LTD.
No. 1558 Longjiang Bei Road
Changzhou City, Xinbei District
China-213 127 Chunjiang Town, Jiangsu Province

EDQM Certificate of Suitability
CEP No R1-CEP 2008-074-Rev 00
Annex 1 Page 1/ 1

3.Management system

The company is in charged by General Manager. The organization is built according to GMP, include Quality (QA and QC), Production, Equipment, Materials, Sales, Financial and Admin.

Organization Chart



Quality Management



Quality Control



Key Person

Name	Title	Working experience	Remarks
Shi Weiming	General Manager	28 years	
Li Fanbao	Consultant	35 years	Senior Engineer
Liao lifeng	Qualified Person	16 years	Engineer
Wang Xiaoliang	Production Manager	15 years	
Qian weizhong	Equipment Manager	33 years	
He Yueqin	QA Supervisor	11 years	
Zhao Kai	QC Supervisor	8 years	
Gu Xufeng	Materials Manager	16 years	
Chen Liangxin	Chemical Workshop Manager	12 years	
Sun Shouying	Purification Workshop Manager	11 years	

Quality Assurance

Changzhou Ruiming Pharmaceutical Co., Ltd. has built the quality and document system according to ICH and cGMP requirement. It is independent of production in the form of Quality department (include QA and QC). This system is effective to ensure the API meets its established specifications.

The quality assurance department is involved in all quality-related matters. Every responsibility for both quality and production system are described in written.

Product release

The qualified person is responsible for release the final product.

QA is responsible for reviewing all the batch-related records including batch production records, batch packaging records, deviation report, test records, OOS/OOT investigation reports and batch monitoring records and so on. Qualified person is responsible for confirming the batch-checking results and signing the order of release.

Quality Risk Management

According to risk management SOP, the risk was classified into three types, high risk, medium risk and low risk respectively.

Generally, high risk should be handled immediately, oppositely, low risk do not need to handle. For the medium risk, it could be handled immediately or delayed according to the situation.

Product Quality Reviews

Product quality review is performed once a year covering production, process, quality standard (raw material, final product, and intermediate and in-process product), stability study, statistics and analysis of test results, product quality and other related fields such as change control, deviation, register, complaint and so on.

DOCUMENTATION

All documents are prepared, reviewed and issued according to written procedures.

The documentation system is portioned into three parts：

STP-Standard Technical Procedure

SMP-Standard Manage Procedure

SOP- Standard Operation Procedure

Production

The related STP, SMP and SOP on production are prepared according to the requirement of GMP and character of product. The parameter in process is controlled and monitored strictly.

Rejected Raw materials and packaging materials are not used in the production. Rejected intermediates are not used in the next step and Rejected products are not released.

Production Management



Premises and Equipment

The production area is divided into Synthesis area and Clean Area.

The Synthesis area is about 2700m^2. A relative independent drying room is set for intermediates and crude APIs, respectively. The sale intermediates is dried, blended and packaged in this area.

For intermediates, there is not HVAC system used.

The cleaning area for API is class D. The whole cleaning area is controlled under three stage HVAC system (Primary, middle and high efficiency filter).

The air from has great stive rooms which like crystallization room ,drying room ,blend room are discharged outside and not returned to the HVAC system. The whole system air recirculation is about 30%.

The disinfection method for HVAC is ozone.

In order to prevent contamination and assure the cleaning class, the buffer area is set between clean area and normal area; Pressure control according to GMP requirement.(keep ≥10pa between clean room and normal area, keep ≥5pa among different function rooms which in same grade).

Water system

The drinking water is used in the synthesis process and equipment cleaning in synthesis area. QC should sample and test drinking water once a month .Every year send sample to CDC test.

The purified water is used equipment cleaning in the cleaning area. The two stage reverted osmosis system is adopted to prepared the purified water.

The disinfection method for purified water system is Hydrogen oxydol and pasteurization.

Layout of Purified water system



Main Produce Equipment List

Equipment name	Quantity
Reactor	50
Centrifuge	10
Dryer	8
Mixing machine	3
Pulverizer	4
Micronizer	1

Main Test Instruments List

Test equipment name	Quantity
HPLC	5
GC	2
UV	1
IR	1
Automatic Polarimeter	1
Melting point instrument	1
Karl Fischer moisture meter	1
Microbial limit lab(A&C grade)	1

4.Personnel

The number of employee is 75 now.

There are 25 technologists

Department	Number
Quality (QA and QC)	18
Production	22
Materials	3
Equipment	5
Others	27

5. Product

Tamsulosin Hydrochloride, DMF 023741,FEI：3007086821 For USA and Canada Markets.

Amlodipine Besilate for China and Europe market.

Propafenone Hydrochloride and Felodipine for China market.

Picture of company

Chemical Area



Dryer (SMA)

Cleaning Corridor

Centrifuge in cleaning area

Dryer for final product

IR

UV

HPLC


Agilent Technologies
Infinitely better.
Infinitely better.
Infinitely better.
lenovo

GC

Thanks!